Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL.
Brown
M
M
Department of Infection & Tropical Medicine, Northwick Park Hospital, Harrow, UK. michael.brown@lshtm.ac.uk
Noursadeghi
M
M
Boyle
J
J
Davidson
R N
RN
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D006801:Humans; D007868:Leg Dermatoses / Q000188:drug therapy / Q000473:pathology; D007892:Leishmania braziliensis; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008081:Liposomes; D008297:Male
D000981:Antiprotozoal Agents; D008081:Liposomes; D000666:Amphotericin B